US FDA Gets Earful On Biologic ‘Umbrella’ Exclusivity, Patent Listings, Biosimilar Bridging Study Waivers

 
• By Sue Sutter
  
Man with hearing problem on grey background, closeup
US FDA heard plenty of feedback from industry trade groups on issues involving biosimilar competition and product innovation.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics